Oct 16,2024

Cognito Therapeutics Publishes Study Demonstrating Structural Brain Preservation in Alzheimer’s Disease in Frontiers in Neurology

Cognito Therapeutics has published a study in Frontiers in Neurology showing that its Spectris™ therapy can preserve brain structure in Alzheimer’s disease (AD). The study, from the OVERTURE Phase 2 clinical trial, found that daily Spectris treatment preserved the corpus callosum, a crucial brain structure for cognitive function, in patients with mild to moderate AD, while those in the sham-treated group experienced notable atrophy. This preservation of brain structure could slow cognitive decline, positioning Spectris as a potential disease-modifying therapy, offering a non-drug-based approach to treating AD.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Oct 07,2024

Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring the technology from Waveform Technologies in January 2024.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 04,2024

Patients conflicted on AI in healthcare

Mark Polyak, president of analytics at Ipsos, says patients are comfortable with AI for administrative tasks and the promise of faster diagnosis, but it becomes an issue when human involvement is taken away and AI is asked to think on its own.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Oct 02,2024

ChatGPT Shows Human-Level Assessment of Brain Tumor MRI Reports

Researchers at Osaka Metropolitan University tested GPT-4 based ChatGPT's ability to assess brain tumor MRI reports against human radiologists. Analyzing 150 preoperative reports written in Japanese, ChatGPT achieved a diagnostic accuracy of 73%, compared to 72% for neuroradiologists and 68% for general radiologists. The AI's accuracy improved to 80% when using neuroradiologist reports but dropped to 60% with general radiologist reports. The findings suggest ChatGPT's potential to assist in brain tumor diagnosis, with researchers planning to explore its use in other imaging fields to enhance diagnostic accuracy and support physicians.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Sep 27,2024

New clinical data demonstrate excellent lesion durability with PulseSelect™ Pulsed Field Ablation System in real-world setting as approvals and adoption expand globally

Medtronic announced clinical results for its PulseSelect™ Pulsed Field Ablation (PFA) System, demonstrating a high rate of durable lesion formation for treating atrial fibrillation (AFib). The study showed 98% durable isolation in pulmonary veins and successful vein isolation in 96% of patients after two months. These findings support PulseSelect's effectiveness in AFib treatment and add to real-world evidence of its safety and durability. The system, widely adopted globally, has received regulatory approvals in China, Australia, and Japan, enhancing AFib care across the Asia Pacific region.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Sep 30,2024

Jackson Health System projects 47% reduction in carbon emissions from patient monitors with Philips next generation monitoring platform

Royal Philips and Jackson Health System conducted a Life Cycle Assessment (LCA) to measure the environmental impact of transitioning to Philips' next-generation patient monitoring systems across three Miami hospitals. The study found that the new monitors could reduce carbon emissions by 47%, saving 685.1 tons of CO2e over the system’s lifespan. This shift also eliminates the need for 420,000 disposable batteries and millions of paper sheets, potentially saving $1.2 million over 10 years. Jackson Health emphasizes that the upgrade balances technological advancement with environmental sustainability, enhancing patient care while reducing waste.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Aug 20,2024

Management of Prolonged Aerobic Exercise in People With Type 1 Diabetes on Automated Insulin Delivery Systems: A Randomized Controlled Study

A randomized controlled trial compared three strategies - raising glucose targets, consuming carbohydrates, and a combination of both—for managing blood glucose during prolonged aerobic exercise in individuals with type 1 diabetes using automated insulin delivery (AID) systems. Results showed that setting a higher glucose target before and during exercise was more effective at maintaining stable glucose levels compared to carbohydrate intake or a combination of both strategies. This approach led to improved time in target glucose range and lower insulin delivery. The study highlights the importance of personalized strategies to manage glycemia during physical activity for better diabetes care.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Aug 14,2024

Empowering Hospitalized Patients With Diabetes: Implementation of a Hospital-wide CGM Policy With EHR-Integrated Validation for Dosing Insulin

A study at Stanford Health Care assessed the feasibility and acceptance of a hospital-wide continuous glucose monitoring (CGM) policy integrated with electronic health records (EHR) for insulin dosing. From November 2022 to August 2023, 135 patients used the protocol, which included personal CGMs like Dexcom G6 and FreeStyle Libre 2. Results showed that 87.8% of CGM validation attempts met accuracy criteria, and 80% of nurses preferred CGM over traditional fingerstick monitoring. Patient feedback was also positive, indicating effective interactions with nursing staff. The study concluded that the CGM policy is feasible and well-received, suggesting potential for broader implementation.

CLINICAL STUDY

#cgm

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Sep 23,2024

Early Dysglycemia Is Detectable Using Continuous Glucose Monitoring in Very Young Children at Risk of Type 1 Diabetes

A study from the Australian ENDIA project investigated the use of continuous glucose monitoring (CGM) in young children at risk for type 1 diabetes (T1D). Between January 2021 and June 2023, researchers monitored 31 children with multiple islet autoimmunity (PM Ab+) and 24 control children, ages 4-5. Results showed that PM Ab+ children had higher glucose variability and spent more time with elevated glucose levels compared to controls. CGM was feasible and well-tolerated, revealing early signs of dysglycemia in young children at risk for T1D, consistent with findings in older age groups.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 06,2024

Closed-Loop Insulin Therapy for People With Type 2 Diabetes Treated With an Insulin Pump: A 12-Week Multicenter, Open-Label Randomized, Controlled, Crossover Trial

A study found that closed-loop therapy (combining continuous glucose monitoring with automated insulin delivery) significantly improved glycemic control in people with type 2 diabetes compared to continuous subcutaneous insulin infusion (CSII) plus CGM. Time in range (TIR) increased from 61% to 76%, and other indicators like glucose variability and insulin doses also showed improvement. Sleep fragmentation improved during closed-loop treatment. The study concludes that closed-loop therapy offers better glycemic control than CSII + CGM for this population.

CLINICAL STUDY

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY